Caught Out By PolyNovo’s Fall? Here’s What Bears Saw

PolyNovo’s recent report showed higher revenue but thinner profit margins, a mix that usually reassures long-term holders even as it unsettles short-term traders. For PolyNovo shareholders, the loss over the past year was 37.2%, including dividends. That gap between a busier top line and weaker earnings raises a tougher question. If you were weighing an investment back in October 2025, what clues were already on the table about this squeeze on profitability?

PolyNovo has already moved. See which of 2 high quality undervalued stocks still trade below our estimates.

The Two PolyNovo Stories Investors Were Weighing

The shares cost A$1.29 at the start of the period, so any assessment of PolyNovo began with how much earnings power investors thought sat behind that sticker price.

The bullish narrative pointed to a fair value of A$2.65. This was the price implied if aggressive assumptions came good, anchored in faster MTX uptake, wider chronic wound use, and profit margins assumed to reach 20.8% in 3 years.

The bearish camp put fair value at A$1.20. This was again an expectations-driven figure, focusing on reimbursement pressure, heavier competition around NovoSorb, and future margins assumed to reach only 15.2%.

What The Results Changed For The PolyNovo Debate

The clearest new fact was the result update. PolyNovo reported revenue of A$79.522m in H2 2026 versus A$69.164m in H2 2025, yet net income slipped from A$9.876m to A$7.338m and net margin moved from 14.3% to 9.2%. That mix of higher sales and weaker profitability challenged the more optimistic margin story and lent more weight to the cautious case.

The useful takeaway is simple. When a thesis leans heavily on future margin expansion, keep checking reported net margin and absolute profit against the earlier promise, rather than focusing only on whether revenue is growing.

What PolyNovo’s Lower Price Asks You To Believe Now

PolyNovo shares now trade at A$0.84, after a loss of 37.2% over the past year from A$1.29. The selected Narrative’s Fair Value sits above the current price, based on a belief that today’s drop masks longer term earnings potential.

The argument leans on NovoSorb’s wider use and already built capacity rather than a fresh expansion story. For that higher figure to make sense, a buyer needs to assume PolyNovo can turn its existing footprint and new plant into sustained, profitable demand for non burn complex wound procedures.

"The main thing that has to go right is converting the existing commercial footprint, manufacturing capacity and upcoming regulatory and reimbursement milestones into deeper penetration of non burn complex wounds across the US and Rest of World markets. The shift of NovoSorb use from large burns into trauma, reconstruction, limb salvage, chronic wounds and plastics points to a broader mix of non burn complex wound cases that can add incremental procedures without relying on infrequent major burn events, supporting a larger and more recurring revenue base."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Looking Beyond PolyNovo’s Wounds

PolyNovo focuses on how damaged tissue heals. Your attention naturally stays on burns, trauma and chronic wounds.

Step back a little and a related question appears. Who is trying to make the actual procedures less invasive in the first place?

Another medical equipment specialist develops robotic systems for surgeons. Its tools aim to make complex operations gentler and more precise.

Those platforms do more than guide instruments. They also collect performance data, build training libraries and support ongoing surgical refinement.

If wound treatments keep evolving, the way surgeons operate matters even more. That is where this other business quietly reshapes the operating room.

It is written up in full, assumptions and all. → Explore the Narrative that puts this company 18% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com